Weekly Marketing Briefing: Cosentyx

Week ending August 23, 2026

1. How AI is currently framing the brand

AI answers frame Cosentyx primarily as a clinically differentiated IL-17A biologic, with convenience and mechanism—not outright superiority—as the main positioning themes. The dominant tone is cautious and advisory: “both are effective options,” “shared decision-making,” and “individual response varies” recur across comparison answers. Safety context is prominent, with infection risk (87 mentions), IBD (40), and hedging/disclaimer language (120) leading the tally. Dosing is generally described as relatively convenient after loading, but the details are not consistently presented.

2. Share of voice vs. named competitors

Competitor references increased materially as response volume returned to 140 from 120 last week:

• Humira: 18 (+9)
• Enbrel: 17 (+9)
• Stelara: 16 (+7)
• Taltz: 16 (+6)
• Remicade: 4 (+4), Skyrizi: 4 (+3), Tremfya: 3 (+1), Rinvoq: 2 (+2)

Humira is currently the largest share-of-voice risk, appearing in every answer set for: “How does Cosentyx compare with Humira for treating plaque psoriasis—are there differences people notice in effectiveness or side effects?” Enbrel is similarly embedded in responses to the “is Cosentyx ‘stronger’?” question, while Taltz dominates the nurse-facing choice question and Stelara appears in all practical-differences answers. The competitive framing is therefore being triggered by explicit comparison queries, not broad brand or mechanism questions.

3. Messaging consistency and content gaps

The clearest gap is dosing accuracy. Answers variously describe a five-week loading regimen, four weekly doses, or maintenance beginning at week 4, week 5, or week 8. This is a high-priority content-production issue because the PI dosing question directly requests an actionable answer. Commission an authoritative, indication-specific dosing hub with regimen tables, timeline graphics, device distinctions, and clear country/label versioning.

The switching and substitution questions also lack a strong owned narrative. AI repeatedly defaults to practical concerns—“coverage, logistics, time-to-response”—when discussing switches from another IL-17, while biosimilar answers inconsistently imply that secukinumab biosimilar substitution may already be available. Create verified explainers for switching to Cosentyx, prior authorization, and generic vs. biosimilar vs. therapeutic alternative, with regularly updated market-status information.

Finally, differentiation content is mechanism-heavy but generic: “Cosentyx targets IL-17A” is repeated, while patient-relevant implications are less consistently explained. A comparison framework covering mechanism, indication, dosing, administration, safety considerations, and evidence boundaries could improve AI retrieval and reduce competitor-led framing.

4. Overclaim / compliance-adjacent language watch

There were 33 overclaim-language hits, up from 28 last week. Reviewers should be aware that AI-generated answers currently circulate terms such as “best,” “stronger,” “superior,” “most effective,” “leading,” and “strongest.” These appear especially in Cosentyx–Taltz, Cosentyx–Enbrel, dosing-convenience, and marketing-versus-guidance answers. They are generated-answer signals—not claims authored by the marketing team—but warrant monitoring and corrective source content.

5. Recommended actions

1. Prioritize a medically reviewed dosing hub to resolve the four-/five-dose and week 4/5/8 inconsistencies.
2. Commission comparison pages for Humira, Enbrel, Taltz, and Stelara, using neutral, evidence-qualified language and patient decision drivers.
3. Build an IL-17 switching and access guide centered on prior authorization, logistics, onset expectations, and tolerability discussions.
4. Publish a generic/biosimilar substitution explainer with current jurisdiction-specific status and pharmacist/prescriber guidance.
5. Strengthen safety and label content on infection, IBD, pregnancy, vaccines, and contraindications to reduce the 26 cross-response inconsistency flags.